Wide Ranks

ADVM

Adverum Biotechnologies, Inc.

6.45

Top Statistics
Market Cap 134 M Forward PE -1.49 Revenue Growth 0.00 %
Current Ratio 5.82 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5470 Enterprise / Revenue 54.20 Price To Sales Trailing12 Months 134.18
Profitability
Profit Margins 0.00 % Operating Margins -2922.10 %
Balance Sheet
Total Cash 153 M Total Cash Per Share 7.37 Total Debt 73 M
Total Debt To Equity 50.84 Current Ratio 5.82 Book Value Per Share 6.93
All Measures
Short Ratio 927.00 % Message Board Id finmb_207074711 Fax 650 649 1995
Shares Short Prior Month 1 M Return On Equity -0.7626 City Redwood City
Uuid 225fcb08-92be-3343-b3b8-e211673ed161 Previous Close 6.16 First Trade Date Epoch Utc 1 B
Book Value 6.93 Beta 1.01 Total Debt 73 M
Volume 290549 Price To Book 0.9310 Last Split Date 1 B
Fifty Two Week Low 5.69 Total Cash Per Share 7.37 Total Revenue 1000000
Shares Short Previous Month Date 1 B Target Median Price 32.00 Max Age 86400
Recommendation Mean 1.38 Sand P52 Week Change 0.3133 Operating Margins -2922.10 %
Target Mean Price 29.71 Net Income To Common -94111000 Short Percent Of Float 0.0739
Implied Shares Outstanding 20 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 365320 Average Volume10days 365320 Total Cash 153 M
Next Fiscal Year End 1 B Revenue Per Share 0.0590 Held Percent Insiders 0.1167
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 6.16 Target Low Price 10.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 7.34 Open 6.22 Free Cashflow -47602500
State CA Dividend Yield 0.00 % Return On Assets -0.2983
Time Zone Short Name EST Trailing Eps -5.95 Day Low 6.20
Address1 100 Cardinal Way Shares Outstanding 20 M Price Hint 2
Target High Price 40.00 Website https://adverum.com 52 Week Change -0.2027
Average Volume 210173 Forward Eps -5.33 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 554.10 % Last Split Factor 1:10
Regular Market Day High 6.46 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 50.84 Fifty Two Week High 29.70 Day High 6.46
Shares Short 1 M Regular Market Open 6.22 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 54.20 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0734 Operating Cashflow -85541000 Currency USD
Time Zone Full Name America/New_York Market Cap 134 M Is_nasdaq_100 False
Zip 94063 Quote Type EQUITY Industry Biotechnology
Long Name Adverum Biotechnologies, Inc. Regular Market Day Low 6.20 Held Percent Institutions 0.7915
Current Price 6.45 Enterprise To Ebitda -0.5470 Financial Currency USD
Current Ratio 5.82 Industry Disp Biotechnology Number Of Analyst Opinions 7
Country United States Float Shares 12 M Two Hundred Day Average 9.62
Enterprise Value 54 M Price To Sales Trailing12 Months 134.18 Forward PE -1.49
Regular Market Volume 290549 Ebitda -99024000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.

Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.

The company is developing ADVM-062 (AAV.

7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.

Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.

Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.